ReadoutIn window
EMD Serono Research & Development Institute, Inc. — Avelumab
Phase 3 primary completion: Avelumab Program Rollover Study.
- Date
- Nov 2026
- Type
- Readout
- Indication
- Solid Tumors
ReadoutIn window
Phase 3 primary completion: Avelumab Program Rollover Study.
The weekly brief is free. Pro adds reminders 7 days and 1 day before.